scholarly journals Daclatasvir Plus Sofosbuvir With and Without Ribavirin for Previously Treated or Untreated Chronic HCV Infection Genotype 1, 2 and 4 in Togo

2020 ◽  
pp. 1-5
Author(s):  
Gamal Shiha ◽  
Folly Anyovi ◽  
Reham Soliman ◽  
Lidaw Déassoua Bawe ◽  
Albert Theophane Yonli ◽  
...  
Keyword(s):  
Liver Fibrosis ◽  
Hcv Infection ◽  
Efficacy And Safety ◽  
Genotype 1 ◽  
High Efficacy ◽  
Previously Treated ◽  
Chronic Hcv Infection ◽  
Group 2 ◽  
Chronic Hcv ◽  
Group 1

Background: Daclatasvir (DCV) is a potent, pangenotypic nonstructural protein 5A inhibitor with demonstrated antiviral efficacy when combined with sofosbuvir (SOF) with or without ribavirin (RBV) in patients with chronic hepatitis C virus (HCV) infection. We are using SOF-DCV combination for large scale treatment. Objectives: The aim of the current study was designed to investigate the efficacy and safety of sofosbuvir/daclatasvir, with or without ribavirin for previously treated or untreated in treatment of HCV genotype 1, 2 and 4, as well as their effect on the liver fibrosis. Methods: One hundred twenty-seven patients with chronic HCV infection were categorized into 2 groups. The group 1 comprised treatment naïve patients, with total serum bilirubin ≤ 1.2mg/10-1L, serum albumin ≥ 3,5g/10-1L, ALAT ≥ 3N, ASAT≤ 2N and platelets count 150 x 109 /L. The group 2 included Peg-INF-alpha or sofosbuvir treatment-experienced patients or patients having at least 2 of the following characteristics: total bilirubin ≤ 1.2mg/10-1L, serum albumin ≥ 3,5g/10-1L, ALAT ≥ 3N, ASAT ≤ 2N and platelets count 150 x 109 /L. The first group was treated with sofosbuvir/daclatasvir for 12 weeks except sofosbuvir treatment experienced patients, who were treated with sofosbuvir/daclatasvir + ribavirin for 24 weeks, with generic medications: DCV 60 mg plus SOF 400 mg ± ribavirin (RBV) within the treatment of hepatitis C virus infection. Efficacy and safety were assessed, and baseline factors associated with sustained virological response at post-treatment week 12 (SVR12) were explored. Results: Sustained virological response (SVR12), was 95,8% in group 1 and 93,8% in group 2. Such high efficacy was accompanied with tolerable adverse effects as well as with significant improvement in liver fibrosis. Conclusion: SOF plus DCV with or without ribavirin achieved high efficacy and safety in HCV genotypes 1,2 and 4 patients. Their effect was accompanied with attenuation of liver fibrosis. Further wider-scale studies are needed to evaluate the actual role of IL 18 polymorphism in treatment response with Sofosbuvir/Daclatasvir.

scholarly journals Real-life data on the efficacy and safety of ombitasvir/paritaprevir/ritonavir + dasabuvir +ribavirin in the patients with genotype 1 chronic hepatitis C virus infection in Serbia

2019 ◽  
Vol 76 (5) ◽  
pp. 531-536 ◽  
Author(s):  
Jasmina Simonovic-Babic ◽  
Ksenija Bojovic ◽  
Milotka Fabri ◽  
Tatjana Cvejic ◽  
Petar Svorcan ◽  
...  
Keyword(s):  
Real Life ◽  
Efficacy And Safety ◽  
Genotype 1 ◽  
Viral Response ◽  
Life Data ◽  
Real Life Data ◽  
End Of Treatment ◽  
Chronic Hepatitis C Virus ◽  
Chronic Hcv Infection ◽  
Chronic Hcv

Background/Aim. The era of direct-acting antiviral (DAA) regimen in the treatment of chronic hepatitis C virus (HCV) started in 2011. The aim of this study was to assess the antiviral efficacy and safety of DAA regimen, ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) + dasabuvir (DSV) + ribavirin (RBV), in patients with chronic HCV infection, genotype 1. Methods. The real-life data were collected. The study was multicentric and included seven infectious diseases and hepatology departments in Serbia. A total of 21 patients were enrolled in the OBV/PTV/r + DSV + RBV early access program, 20 of which were previously treated with pegylated interferon + RBV, while 1 was treatment-naive. All patients received the adequate doses of these antiviral drugs. RBV was not given to the patients with HCV genotype 1b infection according to the therapeutic protocol. For the majority of patient, the treatment duration lasted for 12 weeks. For the patients with liver cirrhosis, who were infected with HCV genotype 1a, the duration of treatment was 24 weeks. Viremia was assessed at four points in time: at baseline, 4 weeks after the treatment beginning (rapid viral response, RVR), 12 or 24 weeks after the treatment beginning (end of treatment response ? ETR) and 12 weeks after the end of treatment (sustained viral response ? SVR). SVR, as a confirmation of the absence of HCV was considered as endpoint of successful treatment. Results. Complete RVR, ETR and SVR were achieved in 64.71%, 85.71% and 95.24% of the patients, respectively. Only 3 patients had mild adverse effects which did not required dose reduction. Conclusion. The treatment of the patients with a chronic HCV infection with OBV/PTV/r + DSV + RBV resulted in excellent antiviral activity and tolerability.

Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection

2014 ◽  
Vol 370 (3) ◽  
pp. 211-221 ◽  
Author(s):  
Mark S. Sulkowski ◽  
David F. Gardiner ◽  
Maribel Rodriguez-Torres ◽  
K. Rajender Reddy ◽  
Tarek Hassanein ◽  
...  
Keyword(s):  
Hcv Infection ◽  
Previously Treated ◽  
Chronic Hcv Infection ◽  
Chronic Hcv

Predictors of Liver Fibrosis in Patients with Chronic HCV Infection

2012 ◽  
Vol 32 (6) ◽  
pp. 1522-1529 ◽  
Author(s):  
Bahadır CEYLAN ◽  
Cem YARDIMCI ◽  
Muzaffer FİNCANCI ◽  
Ümit TÖZALGAN ◽  
Gülhan EREN ◽  
...  
Keyword(s):  
Liver Fibrosis ◽  
Hcv Infection ◽  
Chronic Hcv Infection ◽  
Chronic Hcv

scholarly journals Incidence and Predictors of Advanced Liver Fibrosis by a Validated Serum Biomarker in Liver Transplant Recipients

2017 ◽  
Vol 2017 ◽  
pp. 1-8
Author(s):  
Mamatha Bhat ◽  
Kathleen C. Rollet-Kurhajec ◽  
Aparna Bhat ◽  
Amanda Farag ◽  
Marc Deschenes ◽  
...  
Keyword(s):  
Liver Fibrosis ◽  
Liver Transplant ◽  
Hcv Infection ◽  
Serum Biomarker ◽  
Advanced Fibrosis ◽  
Advanced Liver Fibrosis ◽  
Chronic Hcv Infection ◽  
Chronic Hcv ◽  
Liver Transplant Recipients

Background and Aims. Serum fibrosis biomarkers have shown good accuracy in the liver transplant (LT) population. We employed a simple serum biomarker to elucidate incidence and predictors of advanced fibrosis after LT over a long follow-up period.Methods. We included 440 consecutive patients who underwent LT between 1991 and 2013. Advanced liver fibrosis was defined as FIB-4 > 3.25 beyond 12 months after LT.Results. Over 2030.5 person-years (PY) of follow-up, 189 (43%) developed FIB-4 > 3.25, accounting for an incidence of 9.3/100 PY (95% confidence interval [CI], 8.1–10.7). Advanced fibrosis was predicted by chronic HCV infection (adjusted hazard ratio (aHR) = 3.96, 95% CI 2.92–5.36,p< 0.001), hypoalbuminemia (aHR = 2.31, 95% CI 1.72–3.09;p< 0.001), and hyponatremia (aHR = 1.48, 95% CI 1.09–2.01;p= 0.01). LT recipients with more than 1 predictor had a higher incidence of advanced fibrosis, the highest being when all 3 predictors coexisted (log-rank:p< 0.001).Conclusions. Chronic HCV infection, hypoalbuminemia, and hyponatremia predict progression to advanced liver fibrosis following LT. Patients with these risk factors should be serially monitored using noninvasive fibrosis biomarkers and prioritized for interventions.

scholarly journals Non-invasive methods for the diagnosis of liver fibrosis in chronic HCV infection

2019 ◽  
Vol 17 (8) ◽  
pp. 44-47
Author(s):  
A. I. Fazulzyanova ◽  
◽  
S. V. Tkacheva ◽  
A. K. Khusainova ◽  
N. F. Gayfutdinov ◽  
...  
Keyword(s):  
Liver Fibrosis ◽  
Hcv Infection ◽  
Non Invasive ◽  
Chronic Hcv Infection ◽  
Chronic Hcv

scholarly journals Insulin-like Growth Factor Initiates Hepatocellular Carcinoma in Chronic Hepatitis C Virus Patients through Induction of Long Non-coding Ribonucleic Acids AF085935

2021 ◽  
Vol 9 (A) ◽  
pp. 222-228
Author(s):  
Abeer Mostafa ◽  
Noha El-Sayed Ibrahim ◽  
Dina Sabry ◽  
Wael Fathy ◽  
Amany Y. Elkazaz
Keyword(s):  
Diagnostic Marker ◽  
Healthy Individuals ◽  
Ribonucleic Acids ◽  
Key Word ◽  
Chronic Hepatitis C Virus ◽  
Chronic Hcv Infection ◽  
Group 3 ◽  
Group 2 ◽  
Chronic Hcv ◽  
Group 1

Abstract HCV is the most commonly occurring hepatic infection worldwide.  Chronic HCV infection usually complicated with cirrhosis and even HCC with significant morbidity and mortality. The aim of this study to clarify the molecular mechanism by which HCV can induce HCC and identify a new diagnostic marker for early detection of HCC. Methods: 180 participating subject were divided in to three groups. Group 1: 60 healthy individuals (controls).  Group 2: 60 HCV infected patients. Group 3:  60 HCV patients developed HCC. Serum IGF, FOXO and LncRNA AF085935 were evaluated. Results:  Serum IGF was significantly elevated in HCV and HCC patients, while FOXO and LncRNA AF085935 were significantly up regulated in HCC. IGF significantly correlated with and LncRNA AF085935. Conclusion:  HCV can induce IGF with subsequent induction of   LncRNA AF085935 and FOXO. Key word: HCV, HCC, IGF, FOXO and LncRNA AF085935.

Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection

2019 ◽  
Vol 40 (5) ◽  
pp. 1032-1041 ◽  
Author(s):  
Eric Lawitz ◽  
Robert Flisiak ◽  
Manal Abunimeh ◽  
Meghan E. Sise ◽  
Jun Y. Park ◽  
...  
Keyword(s):  
Hcv Infection ◽  
Efficacy And Safety ◽  
Chronic Hcv Infection ◽  
Chronic Hcv
Sign in / Sign up

Export Citation Format

Share Document